By following the investment decisions of some of the savviest private investors, Fund Twenty8 automatically builds you a diversified portfolio of no fewer than 28 EIS-qualifying startups. The portfolio of every iteration of Fund Twenty8 will be added to this page as they finish deploying.
Fund Twenty8-2017 portfolio
Fund Twenty8's 2017 portfolio consists of 32 investments spanning ten sectors. As our portfolio grows and raises further capital, we look forward to seeing its companies succeed.
FUND TWENTY8-2017 PORTFOLIO COMPANIES
Bockatech
ENGINEERING
Interpac
ENGINEERING
Greenspur Renewables
ENVIRONMENT
Naked Energy
ENVIRONMENT
Pass the Keys
MARKETPLACES
Pekama
MARKETPLACES
LuckyTrip
MARKETPLACES
Ambicare
LIFE SCIENCES
Arcis Biotechnology
LIFE SCIENCES
Cipher Surgical
LIFE SCIENCES
EnteroBiotix
LIFE SCIENCES
Gemetix Healthcare
LIFE SCIENCES
Molecular Warehouse
LIFE SCIENCES
MGB Biopharma
LIFE SCIENCES
Metrion Biosciences
LIFE SCIENCES
Fund Twenty8-2016 portfolio
The first Fund Twenty8 closed in 2017 and finished deploying in 2018. By September, the portfolio was valued at 108% (paper value). Its final portfolio is a testament to the fund's mission: to deliver investors a large and diversified portfolio of at least 28 investments.
- 233 investors took part
- Invested a total of £4.55m
- Diversified over 32 investments
- Across 10 sectors
FUND TWENTY8-2016 PORTFOLIO COMPANIES
Dymag
ENGINEERING
Alert Technology
ENVIRONMENT
USIO
ENVIRONMENT
Pekama
MARKETPLACES
Starstock
MARKETPLACES
Celame
MARKETPLACES
Biotechspert
MARKETPLACES
Make it Social
MARKETPLACES
e-Patient Network
HEALTHCARE
Dem DX
HEALTHCARE
Emoquo
HEALTHCARE
SupaPass
MEDIA
Peptinnovate
PHARMA
Re-Vana Therapeutics
PHARMA
Digital Therapeutics
PHARMA
Camallergy
PHARMA
Momentum Bioscience
PHARMA
FutureYou
PHARMA
Metrion Biosciences
PHARMA
Arcis
PHARMA
Register
Get notified when our funds open to new investorS
By submitting your email address, you consent to be contacted by SyndicateRoom regarding our EIS funds. We take your privacy seriously, and will never share your email with third parties. Read our privacy statement or email comments or questions.